Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma.

摘要: Objective To evaluate long-term progression-free survival and overall survival, quality of life, cognitive function in primary central nervous system lymphoma after systemic intraventricular chemotherapy without radiotherapy. Methods A follow-up was conducted on surviving patients having been enrolled a pilot/phase II trial between September 1995 December 2001. Initially, 65 (median age, 62 years) had treated with radiotherapy. All living were contacted, neurological examination, comprehensive neuropsychological testing, quality-of-life assessment, imaging performed. Results Twenty-one all (32 %) 17 30 60 years or younger (57%), respectively, still alive at median 100 months (range, 77–149 months). Nineteen 21 completed investigations; 1 lost to follow-up. In three patients, an exclusively extraneural relapse high-grade non-Hodgkin's diagnosed 9, 31, 40 months, respectively. them experienced complete remission high dose. Neither late neurotoxicity nor compromise life found any the examined. Interpretation Primary polychemotherapy based high-dose methotrexate (MTX) cytarabine (Ara-C) is highly efficient treatment lymphoma. About half can obviously be cured this regimen neurotoxic sequelae compromise. ANN NEUROL 2010;67:182–189